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Summary 
Stimulation of T  cells with antigen results in activation  of several kinases, including protein 
kinase C (PKC), that may mediate the later induction of activation-related  genes. We have examined 
the potential role of PKC in induction of the interleukin 2 (IL-2) gene in T  cells stimulated 
through the T cell receptor/CD3 complex. We have previously shown that prolonged treatment 
of the untransformed T cell clone Ar-5 with phorbol esters results in downmodulation of the 
c~ and/8 isozymes of PKC, and abrogates induction of Ib2 mRNA and protein.  Here we show 
that phorbol ester treatment also abolishes induction of chloramphenicol acetyltransferase  activity 
in At-5 cells transfected with a plasmid containing the Ib2 promoter linked to this reporter 
gene. The IL-2 promoter contains binding sites for nuclear factors including NFAT-1, Oct, NF- 
xB, and AP-1, which are all potentially sensitive to activation of PKC. We show that induction 
of a trimer of the NFAT and Oct sites is not sensitive  to phorbol ester treatment, and that mutations 
in the NF-KB site have no effect on inducibility  of the IL-2 promoter. In contrast, mutations 
in the AP-1 site located at  - 150 bp almost completely abrogate induction of the IL-2 promoter, 
and appearance of an inducible nuclear factor binding to this site is sensitive to PKC depletion. 
Moreover, cotransfections with c-Jbs and c-jun expression plasmids markedly enhance induction 
of the IL-2 promoter in minimally stimulated T cells. Our results indicate that the AP-1 site 
at  - 150 bp represents a major, if not the only, site of PKC responsiveness in the IL-2 promoter. 
S 
timulation of T lymphocytes  by antigen results in the ac- 
tivation of serine/threonine and tyrosine kinases, and later 
in induction of a large number of activation-associated genes 
(reviewed in references 1-3).  One of the best characterized 
of the kinases is protein kinase C (PKC), 1 a family of phos- 
pholipid-dependent serine/threonine kinases that are activated 
as a consequence of increased phosphatidylinositol  turnover 
in stimulated T cells (reviewed in references 4 and 5). Gene 
induction in activated T cells is at least partly mediated by 
PKC, since phorbol esters (alone or in combination with cal- 
cium ionophores)  can activate PKC and gene expression in 
parallel (reviewed  in references  3 and 6). In fact, phorbol esters 
induce a variety of transcription  factors that are capable of 
binding to specific DNA sequences in the promoter regions 
of phorbol ester-inducible genes. Among these is the AP-1 
(Fos/Jun)  transcription  factor, which is newly synthesized 
as well as posttranslationally modified in phorbol ester-stimu- 
1 Abbreviations  used in this paper: CAT, chloramphenicol acetyltransferase; 
PKC, protein kinase C; hGH, human growth hormone. 
lated cells (7, 8), and the NF-KB transcription  factor, which 
is released from a preexisting cytosolic complex with an in- 
hibitory protein upon phorbol ester treatment (9). 
The gene for the lymphokine IL-2, a growth factor for 
T and B cells, is induced within 1-6 h after TCR stimula- 
tion (10, 11), and represents a good model system for inves- 
tigating the relation between PKC activation and lymphokine 
gene induction in T  cells. The sites relevant for induction 
of the II~2 promoter have been exhaustively mapped. Both 
constitutive (Oct) and inducible (NFAT-1, NF-KB, AP-1, and 
CD28RC) DNA binding factors have  been implicated in in- 
duction (11-19). Each of these inducible factors can be in- 
duced by phorbol esters and/or calcium ionophores in T cells 
and other cell types, suggesting the potential  involvement 
of PKC and/or calcium-dependent kinases. Moreover the in- 
duction of c-Fos, a component of the AP-1 family of tran- 
scription  factors (7), is PKC dependent in T  cells (20). 
By itself, the use of phorbol esters has not been sufficient 
to prove the involvement of PKC, since the activity of several 
other kinases and enzymatic processes  can be secondarily  regu- 
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references 2, 5, and 21). In fact the changes in phosphoryla- 
tion of c-Jun in phorbol ester-stimulated fibroblasts  cannot 
be replicated  in vitro with purified PKC (8).  Experiments 
with PKC inhibitors have also been equivocal, since few in- 
hibitors are entirely selective for PKC, and most are toxic 
to untransformed cells at concentrations approaching those 
required for complete inhibition of kinase activity (22).  An 
alternative method for assessing the involvement of PKC has 
relied  on  downmodulation of certain  PKC  isozymes by 
prolonged treatment with high concentrations of phorbol 
esters (23),  a technique that works particularly well in un- 
transformed cells with low biosynthetic rates.  The mecha- 
nism of downmodulation is apparently through recruitment 
of essentially all the enzyme to the plasma membrane, where 
it is rapidly degraded by a protease (24,  25).  Although un- 
transformed cells treated in this manner show an initial acute 
response to the phorbol ester, this response fades rapidly. After 
36-48  h, the treated cells appear  similar to quiescent, un- 
treated T  cells in their growth rates, basal levels of cellular 
kinase activity, and expression  of activation-associated  genes 
(20,  26). 
In murine thymocytes, Western blotting with isozyme- 
specific antibodies indicates that the cz and B PKC isozymes 
are downmodulated by chronic phorbol ester treatment, and 
expression  of the E isozyme is unaffected (27). Depletion of 
the oe and B isozymes by phorbol ester treatment has been 
confirmed by direct measurements of PKC activity in un- 
transformed murine T  cell clones (20,  26).  The residual 
isozyme was not detected since it does not e~ciently phos- 
phorylate the histone substrate used in the standard assays 
for PKC (28). T cells chronically treated with phorbol esters, 
and thus depleted for the oe and ~  PKC isozymes, show no 
gene induction or lymphokine secretion in response to TCR 
ligands (20, 26),  suggesting that these downmodulated iso- 
zymes are required for signal transduction through the TCR. 
A less likely explanation is that chronic phorbol ester treat- 
ment affects an unrelated process  that is independently re- 
quired for gene induction and lymphokine secretion in acti- 
vated T  cells. 
We have used the untransformed, antigen-responsive  T cell 
clone At-5 (20,  29,  30) to identify the PKC-sensitive sites 
in the II.-2 gene promoter. Ar-5 cells show low constitutive 
but strong inducible expression  of nuclear factors that bind 
to sites in the IL-2 promoter. Moreover, induction of chlor- 
amphenicol acetyltransferase (CAT) activity in At-5 cells trans- 
fected with an IL-2 promoter-CAT plasmid, and then acti- 
vated through the TCR, is completely suppressed by chronic 
phorbol ester treatment, thus implicating the oe and ~  iso- 
zymes of PKC in II.-2 gene induction and facilitating the 
identification of potentially PKC-sensitive mechanisms for 
II.-2 gene induction. We show that a major locus of PKC 
responsiveness  in the IL-2 promoter is likely to be the AP-1 
site located at  -150 bp upstream of the transcription start 
site. Analysis of promoter mutations indicates that an intact 
NF-KB site is not required for Ib2 gene induction in Ar-5 
T  cells. 
Materials and Methods 
Plasmids.  The human 5' IL-2-CAT  plasmid (obtained from G. 
Crabtree, Stanford University, Stanford, CA) contains 635 bp of 
the human IL-2  promoter linked to the CAT gene and SV40 poly(A) 
tail as described (31). The routine 5'IL-2-CAT  plasmids pIL-CAT0, 
pIL-CAT2/1  +,  and pIL-CAT2/1-M (obtained from E.  Serfling, 
Universit~t Wiirzburg,  Wiirzburg,  Germany) contain  -2000 to 
-7 bp,  -293 to  -7 bp, and  -293 to  -200 bp region, respec- 
tively, of the routine IL-2 promoter linked to the Herpes simplex 
virus thymidine kinase (tk) promoter placed upstream of the CAT 
gene in the plasmid pBI~AT2 (14). The three human 5' IL-2-CAT 
plasmids bearing mutations in the IL-2KB site (obtained from M. 
Siekevitz, Mount Sinai Medical Center, New York, NY) were as 
described previously  (13). The four mutants in the -150 and -180 
bp AP-1 sites were constructed in the human 5' IL-2-CAT  plasmid 
(30, 31) using uracil-labeled  template DNA, as described (32). Mu- 
tated plasmids were selected by colony hybridizations using the 
mutagenic oligonucleotide, and their identity was confirmed by 
restriction mapping and sequencing (33). The oligonucleotides  used 
for  the  site-directed mutagenesis of the  AP-1 sites were: MI: 
5'CAAAGACTGACTTTATGGTA, M2:  5'CAAAGGGTGACT- 
GAATGGAT, M3:  5'TCTGATGACTCGAGGGAATT,  and M4: 
5'TCTGATGTTGCTTTGGAATT.  The expression  plasmids  BK28 
(human c-Fos, [34]) and pRSV-cJ (human c-Jun, [35]) were used 
for cotransfections.  The control plasmids that lacked the c-Fos and 
c-Jun coding sequences, but possessed the FBJ-MSV proviral LTR 
and the RSV LTR, respectively,  were kindly provided by Dr. E. 
Flemington, Dana-Farber Cancer Institute,  Boston, MA. 
Transfections.  The murine T cell clone At-5 was cultured in "T 
cell medium," consisting of DMEM containing 10% FCS and rat 
T cell growth factor (CR-rTCGF, Collaborative  Research Inc., Lex- 
ington, MA) as a source of IL-2, and other additives, as described 
previously  (29, 30, 36). For PKC depletion, cells  were treated with 
200 nM PMA for 2 d before transfection, and 200 nM PMA was 
included in the culture medium until the cells were harvested. For 
transfections, untreated or PMA-treated cells (2-3  x  107) were 
harvested in log phase growth (m5  x  10  s cells/ml), incubated 
with 10-15 gg of DNA and 100/zg/ml  DEAE-dextran in 2 ml 
DMEM for 30 min at 37~  and split equally into two flasks  con- 
taining 10 ml of T cell medium and coated with rabbit anti-ham- 
ster antibodies, if appropriate. The transfected cells were activated 
the next day, harvested 24 h later, and assayed for CAT activity, 
as described (37). The conversion of 14C-chloramphenicol to its 
acetylated  forms  was  quantified  using  a  Betagen Betascope 
(Waltham, MA). To control for the increase in protein synthesis 
in activated  cells, the protein concentration of cell extracts was mea- 
sured according to Bradford (38) and used to normalize the mea- 
sured CAT activity. In addition, the plasmid pRSVCAT (37) was 
used as a standard for transfection efficiency  of the cells in each 
experiment (30). The enhancerless  plasmid pBL-CAT2 (39) was not 
inducible in transfections and exhibited very low basal transcrip- 
tional activity. 
The stimuli used for activation  were antigen (arsonate-conjugated 
OVA, 100 #g/ml) with 2  x  1@ TA3 APC (29, 36), anti-CD3e 
(1% 145-2Cll hybridoma supernatant [40]) crosslinked either via 
Fc receptors on 2  x  106 TA3 cells or on flasks coated with 300 
gg/ml rabbit anti-hamster antibody (Cappel Laboratories, Cochran- 
ville, PA), or 10-riM PMA plus 100 nM ionomycin. Activation was 
monitored in all experiments by measuring proliferation or Ib2 
secretion (20, 36). We have  noticed that transfected  At-5 cells stimu- 
lated with TA3 cells and antigen or anti-CD3e show consistently 
lower induction of Ib2-CAT activity than cells stimulated with 
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antibody, possibly because  the latter stimulus is capable of cross- 
linking  a  larger  proportion  of surface  TCR/CD3  complexes. 
Nevertheless, all three stimuli yield qualitatively very similar results. 
For most experiments, the use of  anti-CD3 crosslinked with second 
antibody was preferred, because it monitors activation solely through 
the TCK/CD3 complex, uncomplicated by interactions involving 
other cell-surface  receptors such as CD28  (19). 
The quality of the plasmid DNAs used for transfections was 
monitored by checking them all for equivalent content of super- 
coiled DNA by agarose gel electrophoresis, and by cotransfecting 
them with an RSV-hGH (human growth hormone) internal con- 
trol plasmid and monitoring hGH activity in supernatants and ex- 
tracts of unstimulated cells as described (41). Values for intracel- 
lular growth hormone ranged from 3 to 11 ng/2  x  107 cells 48 h 
after transfection, and values of secreted  hGH ranged from 1.85 
to 5.1 ng/2  x  107 cells. At least three independent DNA prepa- 
rations  were tested for each plasmid.  Relative to the wild-type 
human 5' IL-2-CAT plasmid (set to 100%), the transfection efficiency 
of the IL-2 KB mutants was as follows: M1 (80.1%), M4 (62.1%), 
and M5 (60.9%). Similarly, relative to the wild-type human 5' II.- 
2-CAT plasmid (set to 100%),  the transfection efficiency of the 
AP-1 mutants monitored by this assay was as follows: M1 (92.6%), 
M2 (131.4%), M3 (265.4%),  and M4 (123.4%). Cotransfection 
with internal control plasmids  could not be performed in our ex- 
periments, since all the internal control plasmids that we have tested 
were induced in activated T cells, and since induction of the CAT 
plasmids was decreased when internal control plasmids were cotrans- 
fected, apparently because of  competition between the CAT plasmids 
and the internal control plasmids for relevant transcription factors. 
These problems are likely to reflect lower resting, as well as lower 
inducible levels of transcription  factors  in  untransformed T  cell 
clones, compared with the transformed T cells previously used for 
studies of II.-2 promoter activation (JURKAT, EL-4, and LBRM- 
33  [11, 12,  14,  16]). 
Electrophoretic Mobility Shift Assays.  The following oligonucle- 
otides were used as probes in gel-shift assays: Murine Ig K  enhancer 
~cB site (42): 5'gatcCAGAGGGGACTTTCCGAGA; Ylg KB mu- 
tant:  5'gatcCAGAGGGGACTTGAAGAGA;  5'Ig  KB  mutant: 
5'gatcCAGAATTCACTTTCCGAGA; Wild-type murine Ib2 lob 
site (TCEd, [14]): 5'gatcACCAAGAGC~ATTTCACCTAAATCC; 
-150 bp murine AP-1 site (TKEp, [14]): 5'gatcAATTCCAGAG- 
AGTCATCAGA;  -180  bp  murine  AP-1  site  (TREa,  [14]): 5'- 
gatccTAAATCCATTCAGTCAGTGTATG; Murine  NFAT-1 site 
(Pu-boxa,  [14, 15]): 5'gatcC.,CCCAAAGAGGAAAATTTGTTTC- 
ATACAG; Human metallothionein AP-1 site (43): 5'tcgaCGTGAC- 
TCAGCGCGC. 
The  oligonucleotides  were  endlabeled  with  "),[32P]-ATP and 
polynudeotide kinase (33) and purified on 12% acrylamide gels. 
Small-scah nuclear extracts were made from 2  x  107 unactivated 
or activated Ar-5 cells by a modification of the method of Dignam 
(44). Unless otherwise stated, cells were activated for 2 h with anti- 
CD3e antibody which was crosslinked  using immobilized second 
antibody. For each binding reaction, 10,000 cpm (,~0.2-0.5 ng) 
of endlabeled probe was incubated with 5-8-~g nuclear extract in 
the presence of 3/~g sheared  poly(dI-dC). The binding reaction 
was performed for 5-10 rain (AP-1), or 15-20 min (NFAT-1 and 
ID2KB) at room temperature. The resulting complexes were ana- 
lyzed by electrophoresis at room temperature on 4%  acrylamide 
gels  (33). 
Results and Discussion 
Induction of the IL2 Promoter Is Sensitive to Chronic Phorhol 
Ester Treatment.  The antigen-responsive murine T cell done 
Ar-5 (29) was left untreated or depleted of PKC by prolonged 
treatment  with a high concentration of PMA  (200 nM for 
48 h). As mentioned previously, this treatment results in sdec- 
tire degradation of the ot and B isozymes of PKC, but not 
the e isozyme in murine thymocytes (27), and abrogates in- 
duction of IIr  mRNA in At-5 cells (20). Untreated and PMA- 
treated cells were transfected with plasmids  containing the 
5' sequences of either the human or murine Ib2 promoters 
linked  to the CAT reporter gene (14,  31).  The transfected 
Figure 1.  Sensitivity  of  the IL-2  promoter 
to PKC depletion by chronic phorbol ester 
treatment. (a) A schematic  diagram of the 
Ib2 promoter,  showing  the locations  of  sites 
thought to be important for promoter in- 
duction. (') Weaker binding sites. (b) In- 
duction of CAT activity after transfection 
of the indicated plasmids into At-5 cells. 
Untreated cells or cells treated  for 48 h with 
the phorbol ester PMA were transfected 
with human (left)  or murine (center) 5'IL 
2-CAT plasmids or with a plasmid con- 
taining a trimer of  the NFAT  and OCT sites 
(right), and stimulated with TA3 cells and 
antigen or anti-CD3e. A representative  ex- 
periment using TA3 cells and anti-CD3e 
is shown. At least three similar  experiments 
were performed with independent prepa- 
rations of each plasmid. 
855  Jain et al. cells were stimulated 24-h later with either antigen (arsonate- 
conjugated OVA; Ars-OVA) (29) presented on TA3 cells, or 
with  a mAb to  the TCR/CD3  complex (145-2Cll,  anti- 
CD3e) that was crosslinked using either TA3 cells or an im- 
mobilized second antibody. The cell extracts were assayed 
for CAT activity 18-24  h  later (37). 
Both human and murine 5' IL-2-CAT constructs were in- 
duced three-fivefold after activation of At-5 cells by TA3 cells 
and antigen or anti-CD3 (Fig.  I b, left and center). No induc- 
tion was seen if the cells were depleted of PKC by phorbol 
ester treatment (Fig.  1 b, left and center).  This was expected 
since IL-2 mILNA and protein are not induced after chronic 
phorbol ester treatment (20). The plasmid pRSVCAT, which 
is constitutively expressed, was used as a control for transfec- 
tion efficiency and was equivalently expressed in untreated 
and PMA-pretreated cells (see Fig. 2). The PMA-pretreated 
ceils did not proliferate in response to PMA and ionomycin 
nor to anti-CD3e antibody, confirming that they were depleted 
of the relevant (or and 3) PKC isozymes (data not shown). 
Induction  of an  NFAT/Oct  Trimer  Is  Insensitive  to  Chronic 
Phorbol  Ester  Treatment.  The human and mouse IL-2 pro- 
moters share binding sites  for several known transcription 
factors in the region extending "o300 bases upstream of the 
transcription start site (see Fig.  1 a). This region contains 
sites for the nuclear factors NFAT-1, Oct-I/Oct-2,  NF-KB, 
CD28RC,  and  AP-1  (11-19).  NFAT-1, AP-1,  and  NF-KB 
binding activities have been shown to be induced by phorbol 
esters and/or calcium ionophores in T  cells (JURKAT [12, 
13] and EL-4 cells [14]),  and in other cell types (7, 45, 46), 
implicating PKC and/or calcium dependent kinases in their 
activation. 
To determine whether the NFAT-1 and Oct sites contributed 
to the PKC responsiveness  of the II.-2 promoter, we trans- 
fected a CAT plasmid (plL-CAT2/1-M;  [14]) containing a 
trimer of the murine NFAT-1/Oct site (-293  to  -200 bp 
relative to  the  transcription  start  site)  into  untreated and 
phorbol ester-treated Ar-5 ceils (Fig.  1 b, right).  The NFAT- 
1/Oct construct was induced strongly under both conditions 
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by mutations of the KB site that abolish NF-KB  binding. 
(a) Induction of  CAT activity from wild-type (lanes 3-6) 
and KB site mutant promoters (lanes 7-18) after transfec- 
tion into untreated Ar-5 cells (lanes I, 3, 4, 7, 8, 11, 12, 
15, and 16) or cells  depleted  of  PKC by pretreatment with 
the phorbol ester PMA (lanes 2, 5, 6, 9, 10, 13, I4, 17, 
and I8). Cells were either unstimulated (lanes I-3, 5, 7, 
9, 11, 13, 15, and 17) or stimulated with anti-CD3e cross- 
linked with immobilized second antibody (lanes 4, 6, 8, 
I0,  12,  14,  16,  and I8). One representative  experiment 
of four performed with  each plasmid, is  shown. The 
plasmid pRSVCAT was used as a control for transfecta- 
bility of the untreated (lane I) or PMA downregulated 
Ar-5 cells  (lane  2). (Tbp)  Sequences  of the KB site mutants 
M1, M4, and M5 are compared  with the sequences  of the 
wild-type ID2 r,B site and the Ig K  gene enhancer KB site. 
(b) Binding  of  an inducible  NF-KB-like  nuclear  factor  from 
Ar-5 cells to the IL-2KB  site. Cells were untreated (lane 
1) or activated  with crosslinked  anti-CD3e (lanes 2-10), 
nuclear extracts were prepared, incubated with a labeled 
oligonucleotide  containing the IL-2KB  site in the presence 
or absence  of unlabeled competitors as indicated, and ana- 
lyzed by electrophoretic mobility shift assay. (~1) Posi- 
tions of the free probe and the inducible retarded com- 
plex. (Tbp)  Sequences  of the relevant  regions of the IL2~B 
probe and of the unlabeled competitors. 
(Fig.  1, b, right).  Although this experiment does not distin- 
guish between the individual contributions  of NFAT-1 and 
Oct  sites,  it is clear that downmodulation  of PKC activity 
(or any other effect of chronic PMA pretreatment) does not 
compromise their enhancer function in At-5 cells. Likewise, 
phorbol ester treatment did not affect the induction of a pro- 
tein complex that bound  specifically to the NFAT-1 site in 
gel-shift assays  (see Fig. 3  b, lanes 9-12).  The lack of effect 
of PKC depletion on induction  of the NFAT-1  site trimer, 
and on appearance of NFAT-1 binding activity in a gel-shift 
assay, is consistent with the suggestion that calcium-dependent 
processes may be involved in the activation of NFAT-1 (18). 
However PKC isozymes (such as the ~ isozyme) that are not 
downmodulated by chronic phorbol ester treatment  might 
also be involved (27). 
Mutations in the NF-KB Site Do Not Decrease IL-2 Promoter 
Induction.  These experiments suggested that the NFAT and 
Oct sites were not PKC responsive (as defined by their insen- 
sitivity to chronic phorbol ester treatment),  and hence that 
the PKC-responsive site(s) were located downstream of -  200 
bp in the IL-2 promoter. Two likely candidates were the NF- 
KB and AP-1 sites (Fig. 1 a), which can bind purified NF-KB 
and AP-1 proteins as well as PMA-inducible nuclear factors 
from activated T  cells in vitro (13, 14, 42, 47). We used site- 
specific mutants to determine the importance of the NF-KB 
site in IL-2 promoter induction. Three 5' IL-2-CAT plasmids 
derived from mutations in the NF-KB site of the human IL-2 
gene (13) (Fig. 2 a, top) were transfected into At-5 cells. All 
three mutant  promoters  (Fig.  2  a,  lanes  7,  8;  11,  12;  and 
15 and 16) could be activated at least as well as the wild-type 
promoter  (lanes 3  and  4).  The lack  of effect of mutations 
in  the  site was  not  due  to any differences in  the ability of 
the plasmids to be transfected as determined by the internal 
controls (see Materials  and Methods).  In fact, mutants M4 
and M5 (lanes 11,  12;  and  15,  16) consistently showed two 
to fourfold higher induction  than  the wild-type promoter 
(lanes 3 and 4), despite being lower in transfection efficiency. 
This  suggests  that  perhaps  the IL-2 NF-KB  site is a  target 
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AP-1 site markedly decrease induction  of the II-2 pro- 
motet in vivo. (a) Induction  of  CAT activity from wild- 
type (lanes 2  and 3)  and mutant (lanes 4-7)  I1:2 
promoters  after transfection into Ar-5 cells. Lane I 
shows the activity obtained after transfection of the 
control pKSVCAT plasmid. Lanes 1 and 2, unstimu- 
lated cells; lanes 3-7, cells stimulated with crosslinked 
anti-CD3e. One representative experiment, of six to 
eight using different methods of activation, is shown. 
There was no difference in the background activity 
of the wild-type and mutant promoters in unstimu- 
lated cells. (~p) Sequences of the mutations in the 
two AP-1 sites of the IL-2  promoter. (b) PKC-sensitive 
binding of a nuclear factor from activated Ar-5 cells 
to the downstream AP-1 site of the I1:2 promoter. Cells 
were untreated (" -  "; lanes I, 2, 5, 6, 9, and I0) or 
depleted of kinase C by prolonged exposure to the 
phorbol ester PMA ("+"; lanes 3, 4, 7, 8, II, and 12), 
and left unstimulated ("/3"; lanes I, 3, 5, 7, 9, and 
11), or induced with crosslinked anti-CD3 ("F'; lanes 
2, 4, 6, 8, 10, and 12).  Nuclear extracts were made, 
incubated with labeled oligonucleotides corresponding 
to the - 150 AP-1 site (lanes 1-4), the metallothionein 
AP-1 site (lanes 5-8), or the NFAT-1  site (lanes 9-12), 
and analyzed by electrophoretic mobility shift assay. 
The positions of the free probes and of the inducible 
retarded complexes are indicated. 
858  AP-1 and NFgB Sites in the Interleukin 2 Promoter for negative regulation in Ar-5 cells.  In contrast,  the same 
NF-KB mutations have been reported to decrease induction 
in PHA/PMA-stimulated JURKAT cells by as much as 80% 
(13).  This discrepancy may reflect a difference between pri- 
mary and transformed T cells. Alternatively, stimulation via 
PMA and PHA may not physiologically mimic  activation 
by antigen or antibodies to the TCR/CD3 complex. Neverthe- 
less, At-5 cells and JURKAT cells are unlikely to have com- 
pletely different requirements  for II.-2 promoter activation, 
since a mutant promoter with an internal  deletion encom- 
passing the NF-KB site was induced as well as the wild-type 
IL-2  promoter  in  PHA/PMA-stimulated  JURKAT  cells 
(12, 48). 
Like induction  of the wild-type promoter,  induction  of 
the IL-2 t~B site mutants was also abrogated by PMA pretreat- 
ment (Fig. 2 a, lanes 5, 6; 9, 10; 13, 14; and 17,  18). This 
result confirms that  the NF-KB site does not represent  the 
PKC-responsive site in the I1.-2 promoter.  The II.-2 KB site 
binds purified NF-IcB in vitro with "~,10-fold lower affinity 
than the Ig tcB site (49), and its activity in vivo may be fur- 
ther reduced or modified by interactions with other nuclear 
factors (47, 50); thus, it is not surprising that it appears non- 
functional  in our  assays. 
Although mutations in the NF-KB site did not alter the 
induction  of IL-2-CAT activity, we detected binding  of an 
inducible nuclear factor to the NF-KB site in gel-shift assays 
(Fig. 2 b). A double-stranded oligonucleotide spanning the 
murine Ib2 riB site (-210 to  -186 bp) was labeled and in- 
cubated with nuclear extracts from At-5 cells that were ei- 
ther unstimulated or stimulated with crosslinked anti-CD3e. 
Two specific retarded bands were observed with nuclear ex- 
tracts from stimulated, but not unstimulated cells (Fig. 2 b, 
lanes 1 and 2). The upper band migrated with the same mo- 
bility as the retarded bands  seen with  a labeled (Ig)  ~ en- 
hancer  KB probe (data not  shown).  The lower and fainter 
band appeared variably and may result from proteolytic degra- 
dation of the upper band. The binding was competed by un- 
labeled oligonucleotides corresponding to the labeled IL-2 ~B 
probe (Fig.  2 b, lanes 3 and 4, "se/f"), as well as by oligonu- 
cleotides containing the Ig KB site (Fig. 2 b, lanes 5 and 6). 
Ig KB oligonucleotides containing mutations in the 5' invar- 
iant GGG (similar  to the M1 mutation in IL-2 ~B, lanes  7 
and 8 "5' Mut") or in the 3' TTCC (similar to the M4 muta- 
tion in IL-2 t~B, lanes 9 and 10, "3' Mut") failed to compete 
for binding (Fig. 2 b). The factor therefore., behaved as predicted 
for authentic NF-~B (13, 42). The discrepancy between the 
binding seen in the gel-shift experiments and the lack of effect 
in  transfection  assays  emphasizes  the  importance  of cor- 
roborating in vitro binding analyses  with experiments per- 
formed in vivo. 
Mutations  in the Downstream AP-I Site Abrogate  11_,2 Pro- 
moter Induction.  We also investigated the role of both AP-1 
sites in induction of the II.-2 promoter. Two AP-1 sites have 
been identified by deletion and footprinting analysis at  -  150 
and  -180 bp upstream of the transcription start site (12, 14, 
15, 30) (Figs.  1 a and 3 a). The upstream AP-1 site at  -180 
bp is not detected by footprinting  of Eb4 nuclear extracts 
(14), and deletion of the site does not affect induction of the 
II.-2 promoter in JURKAT cells (12). However, this site has 
been implicated in the synergistic response to Ibl of LBRM-33 
cells (16). By contrast, deletion of the downstream AP-1 site 
at  - 150 bp decreases induction to 11% of the wild-type level 
in JURKAT cells, and to 27% of the wild-type level in EL-4 
cells (12, 14). This site binds inducible nuclear proteins from 
EL-4 cells, and has a higher affinity for purified AP-1 proteins 
than the  -180 bp site (14). We made site-specific  mutations 
in both AP-1 sites and transfected the mutants into Ar-5 cells 
(Fig.  3, a  and  b). 
Both mutations in the downstream (-150 bp) AP-1 site 
significantly decreased II.-2 promoter activity in transfection 
experiments.  Mutant M3, bearing a triple base mutation (AAA 
to CTC) showed a "-,95% decrease in the induction of CAT 
activity in response to crosslinked anti-CD3e (Fig. 3 a, bottom), 
and a 60-80%  decrease in response to TA3 cells and anti- 
CD3e or PMA and ionomycin (data not shown). If normal- 
ized  with  respect  to  wild-type  plasmid  for  transfection 
efficiency, induction of the mutant M3 promoter would be 
decreased by two to threefold further (see normalized hGH 
values in Materials and Methods).  Mutant M4, which also 
bears a triple mutation (AGT to CAA) showed no response 
at all to any stimulus tested (>95% decrease, Fig. 3 a, bottom, 
and data not shown), although the plasmid was transfected 
better than the wild-type. In contrast the M1 and M2 muta- 
tions in the upstream AP-1 site only partly decreased induc- 
tion in response to these various stimuli (25-65% decrease, 
Fig. 3 a, bottom, and data not shown). These results indi- 
cate that the downstream AP-1 site is absolutely required for 
induction of the II.-2 promoter in response to TCR stimuli. 
The upstream site,  although not critical, may enhance acti- 
vation in vivo. Our mutations monitor the AP-1 site at  - 150 
bp rather than the CD28-responsive site that is located im- 
mediately upstream (19), since they abrogate induction of CAT 
activity in cells stimulated with crosslinked anti-CD3 in the 
complete absence of accessory cells that might express ligands 
for CD28. 
We performed gel-shift assays to determine if either AP-1 
site was capable of binding in a PKC-sensitive manner to in- 
ducible nuclear  factors in vitro.  Radiolabeled oligonucleo- 
tides corresponding to either AP-1 site were incubated with 
nuclear extracts from stimulated or unstimulated Ar-5 cells. 
The  -180 AP-1 site probe failed to bind any strongly induc- 
ible protein (data not shown). These results are in contrast 
to those reported for LBRM cells (16),  and may reflect the 
inability of II.-1 to enhance Ib2 gene induction in Ar-5 cells 
(Jain, J., and A. Rao, unpublished results). In contrast,  the 
oligonucleotide corresponding to the  -  150 AP-1 site bound 
to a nuclear factor found only in activated At-5 cells  (Fig. 
3 b, lanes 1 and 2); an inducible factor of identical mobility 
bound to an oligonucleotide containing the metallothionein 
AP-1 site (Fig. 3 b, lanes 6 and 7). The factor was identified 
as Fos or a Fos-related protein (30).  It was detectable at 30 
min after activation  and was maximally induced at  1-2 h, 
as expected if the rapidly inducible Fos family members were 
involved. Its migration was altered by affinity-purified anti- 
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Figure 4.  Induction  of the Ib2 promoter is augmented  by expression 
of c-Fos and c-Jun. At-5  cells  were  cotransfected  with 2.5/~g of the human 
5' IL-2-CAT  plasmid and 2.5 #g each of the human c-Fos, c-Jun, or con- 
trol expression  plasmids. The cells were activated  with 1% anti-CD3, ei- 
ther soluble (hatched  bars), or crosslinked  with immobilized  second anti- 
body (solid bars). One representative experiment, of three similar ones, is 
shown. 
bodies to the Fos M peptide (51) that were capable  of im- 
munoprecipitating c-Fos and related proteins.  Its binding was 
competed by unlabeled oligonucleotides corresponding to the 
downstream AP-1 site or the metallothionein AP-1 site, but 
not by oligonucleotides containing the IL-2 KB site or the 
M1, M2, M3, or M4 mutations in the AP-1 sites (30).  In- 
duction of the AP-1 factor in Ar-5 cells was sensitive to PKC 
depletion by chronic phorbol ester treatment (Fig. 3 b; com- 
pare lanes 2 and 4 with 6 and 8), although there was no effect 
on induction of NFAT-1 in the same experiment (Fig.  3 b, 
lanes 9-12). 
Cotransfection with c-Fos and c-Jun Expression Plasmids Increases 
IL,2 Promoter Induction.  Fos-Jun complexes are induced after 
TCR/CD3-mediated activation (16, 20) and bind to AP-1 
sites in vitro (7).  We tested the ability of c-Fos  and c-Jun 
expression  plasmids to enhance the induction of IL-2-CAT 
activity in transient cotransfections (Fig.  4).  As high con- 
centrations of plasmid DNA (>10 #g) inhibit transfection 
efficiency in these cells (Valge-Archer, V. E., and A. Rao, un- 
published results), the amount of IL-2-CAT plasmid trans- 
fected was decreased by the amount of c-Fos, c-Jun, or con- 
trol plasmids used.  Under these conditions, the IL-2-CAT 
plasmid cotransfected with control plasmids for c-Fos and 
c-Jun was weakly induced by crosslinked anti-CD3e (4.3-fold 
in this experiment), presumably because the FBJ-MSV and 
RSV  LTRs present in the control plasmids competed for 
binding of transcription factors  also required for IL-2 pro- 
moter induction (see Materials and Methods). Cotransfec- 
tion of either c-Fos or c-Jun with IL-2-CAT resulted in in- 
creased induction of CAT activity in stimulated T  cells (to 
27-fold and 13-fold, respectively;  Fig. 4).  Cotransfection of 
both c-Fos  and c-Jun with IL-2-CAT resulted in a 44-fold 
induction of IL-2-CAT. This represents  a  10-fold enhance- 
ment over the control cotransfection (Fig.  4).  In addition, 
cotransfection of either c-Fos alone,  or c-Fos and c-Jun to- 
gether uncovered a threefold induction of IL-2-CAT by soluble 
anti-CD3e, which alone was insufficient to induce IL-2-CAT 
expression. 
Cotransfection of c-Fos and c-Jun, either individually or 
together, did not cause induction of II.,2-CAT activity in un- 
stimulated T cells, confirming that other transcription factors 
such as NFAT-1 are also required for induction. Cotransfec- 
tion with c-Fos alone causes a reproducible three- to fivefold 
increase in the induction of IL-2-CAT activity in stimulated 
T cells, possibly because induction of c-Jun (which is expressed 
in resting cells) is not limiting for AP-1 activity (30). In con- 
trast, cotransfection with c-Jun alone has a more variable effect, 
indicating that induction of c-Fos or other Fos family members 
may be limiting. Cotransfection with c-Fos did not increase 
induction of the AP-1 site mutants M3 and M4 in response 
to crosslinked anti-CD3e (30).  These results are consistent 
with the possibility that c-Fos and c-Jun act to enhance IL-2- 
CAT induction by binding to the  -150 bp AP-1 site, and 
provide further in vivo evidence  for the importance of the 
- 150 AP-1 site for Ib2 promoter activation in untransformed 
T  cells. 
Conclusions.  In summary, we have demonstrated that the 
IL-2 NF-KB site is not required for TCR-mediated induction 
of the IL-2 promoter in an untransformed T  cell clone.  In 
contrast, the AP-1 site at  - 150 is clearly required for induc- 
tion in vivo.  In the absence of any inducible binding with 
the  -180 AP-1 site in gel-shift assays, our results establish 
that the  -150 AP-1 site is a major, if not the only, kinase 
C-responsive site in the IL-2 promoter. Cotransfection with 
c-)bs and c-jun expression  plasmids enhances  IL-2 promoter 
induction, most likely by acting at the AP-1 site at  -150 
bp. However, it remains to be established  which of the var- 
ious Fos/Jun family members actually mediate activation of 
the IL-2 promoter in vivo. 
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